Dynacure
Dynacure develops new treatments for orphan disorders, focusing on CNM through Dyn101 program with Ionis.
France
Series C
Total: $100.27M
Biotechnology, Health Care +2
General Information
Get notified when Dynacure moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track Dynacure
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
France Market
Biotechnology
About Dynacure
Taxonomy: Rare disease drug development, Orphan disorders, Clinical-stage drug development, Antisense medicine, RNA-targeted drug discovery, Dynamin 2 protein modulation, Centronuclear Myopathies (CNM), Ionis Pharmaceuticals partnership, Investigational medicine development, Clinical trial advancement, Biopharmaceutical research, Dyn101 program, Orphan disease therapeutics, Rare disease treatment innovation
Services & Products
Target Customers
Funding Rounds & Investors (3)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Series C | •••••• | 6 |
|
02 Apr 2020 |
| Series A | •••••• | 4 |
|
06 Jul 2018 |
| Seed Round | •••••• | 2 |
|
08 Nov 2016 |
Dynacure Alternatives & Competitors
Focused on the research and development of therapeutics for infectious diseases and rare disorders
Advancing innovative solutions for severe rare diseases
Clinical-stage biopharma company developing novel RNA-modulating drug candidates to treat rare and u...
FAQ About Dynacure
Don't just browse. Track.
Signal Tracker monitors Dynacure and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.